RANI vs RARE · rev $3.4M vs rev $350.0M
Rani Therapeutics Holdings Inc (RANI) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Rani Therapeutics Holdings Inc (RANI) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported RANI revenue for 2026-06-30 was $3.4M. Net income was -$14.4M. Revenue was up 100.0% from 2026-03-31 to 2026-06-30. RANI currently screens at market cap $41.5M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
RANI currently screens at market cap $41.5M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the RANI and RARE stock pages for the full models.
Not investment advice.